Home/Pipeline/QX031N

QX031N

Respiratory Diseases

PreclinicalActive

Key Facts

Indication
Respiratory Diseases
Phase
Preclinical
Status
Active
Company

About Qyuns Therapeutics

Publicly traded biotech developing antibody therapies for autoimmune and allergic diseases with a pipeline targeting IL-4Rα, IL-17A, IL-23, and TSLP pathways.

View full company profile

Therapeutic Areas

Other Respiratory Diseases Drugs